PATENT CLAIM ANALYSIS

Application Number: 16132928
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["424", "138100"]

Abstract:
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.

Claim (Index 30):
A method of treating a mutant isocitrate dehydrogenase 1 (IDH1) enzyme-associated cancer in a subject identified as having an isocitrate dehydrogenase 1 (IDH1) mutation that is present in a nucleic acid, wherein the IDH1 mutation results in the subject expressing an IDH1 polypeptide comprising a R132C or a R132H amino acid substitution, the method comprising:\n administering to the subject a small molecule that inhibits the IDH1 polypeptide comprising the R132C or a R132H amino acid substitution, wherein the small molecule is specific for the mutant IDH1 polypeptide.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.37736
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13060191', '14102730', '15589615', '15238161', '15186188']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7812863968983518
- 35 USC 102 Novelty (BERT): 0.6514158743803071
- Combined Prediction Score: 0.7682993446465473
- Mean Citation Score: 526.99217
- Max Citation Score: 787.84033
- Similarity Product: 581.7400649147689

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test